Clinical Trial Update: Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pemetrexed disodium in stage IV non-small cell lung cancer with poor performance status (ECOG 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed disodium (Pemetrexed disodium)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Stage IV Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-03-18